NOT KNOWN DETAILS ABOUT HEMGENIX

Quantity of eligible sufferers: CDEC talked about the uncertainty in the quantity of patients with moderately severe to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical gurus consulted by CADTH indicated that some sufferers who're classified as having moderate or average ailment could have a extreme bleeding pheno